- Home
- FHTX vs XPER Comparison
FHTX vs XPER Comparison
Compare FHTX & XPER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- XPER
- Stock Information
- Founded
- FHTX 2015
- XPER 1990
- Country
- FHTX United States
- XPER United States
- Employees
- FHTX N/A
- XPER N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- XPER Semiconductors
- Sector
- FHTX Health Care
- XPER Technology
- Exchange
- FHTX Nasdaq
- XPER Nasdaq
- Market Cap
- FHTX 517.9M
- XPER N/A
- IPO Year
- FHTX 2020
- XPER 2003
- Fundamental
- Price
- FHTX $7.74
- XPER $9.59
- Analyst Decision
- FHTX Strong Buy
- XPER Strong Buy
- Analyst Count
- FHTX 5
- XPER 3
- Target Price
- FHTX $16.00
- XPER $19.00
- AVG Volume (30 Days)
- FHTX 184.1K
- XPER 402.9K
- Earning Date
- FHTX 10-31-2024
- XPER 11-06-2024
- Dividend Yield
- FHTX N/A
- XPER N/A
- EPS Growth
- FHTX N/A
- XPER N/A
- EPS
- FHTX N/A
- XPER N/A
- Revenue
- FHTX $35,185,000.00
- XPER $506,058,000.00
- Revenue This Year
- FHTX N/A
- XPER $0.13
- Revenue Next Year
- FHTX $15.40
- XPER $7.57
- P/E Ratio
- FHTX N/A
- XPER N/A
- Revenue Growth
- FHTX 61.95
- XPER N/A
- 52 Week Low
- FHTX $2.70
- XPER $6.89
- 52 Week High
- FHTX $10.25
- XPER $12.29
- Technical
- Relative Strength Index (RSI)
- FHTX 46.15
- XPER 67.51
- Support Level
- FHTX $7.24
- XPER $8.35
- Resistance Level
- FHTX $8.35
- XPER $9.02
- Average True Range (ATR)
- FHTX 0.63
- XPER 0.26
- MACD
- FHTX -0.09
- XPER 0.04
- Stochastic Oscillator
- FHTX 27.49
- XPER 97.25
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.